The phamacogenetics is being used to predict whether the selected chemotherapy will be really effective and tolerable to the patient. Irinotecan,oxidized by CYP3A4 to produce inactive compounds,is used for treatment o...The phamacogenetics is being used to predict whether the selected chemotherapy will be really effective and tolerable to the patient. Irinotecan,oxidized by CYP3A4 to produce inactive compounds,is used for treatment of various cancers including advanced non small cell lung cancer (NSCLC) patients. CYP3A4*16B polymorphism was associated with decreased metabolism of irrinotecan. Irinotecan is also metabolized by carboxylesterase to its principal active metabolite,SN-38,which is subsequently glucuronidated by UGT1As to form the inactive compound SN-38G. UGT1A1*28 and UGT1A1*6 polymorphisms were useful for predicting severe toxicity with NSCLC patients treated with irinotecan-based chemotherapy. Platinum-based compounds (cisplatin,carboplatin) are being used in combination with new cytotoxic drugs such as gemcitabine,paclitaxel,docetaxel,or vinorelbine in the treatment of advanced NSCLC. Cisplatin activity is mediated through the formation of cisplatin-DNA adducts. Gene polymorphisms of DNA repair factors are therefore obvious candidates for determinants of repair capacity and chemotherapy efficacy. ERCC1,XRCC1 and XRCC3 gene polymorphisms were a useful marker for predicting better survival in advanced NSCLC patients treated with platinum-based chemotherapy. XPA and XPD polymorphisms significantly increased response to platinum-based chemotherapy. These DNA repair gene polymorphisms were useful as a predictor of clinical outcome to the platinum-based chemotherapy. EGFR kinase inhibitors induce dramatic clinical responses in NSCLC patients with advanced disease. EGFR gene polymorphism in intron 1 contains a polymorphic single sequence dinucleotide repeat (CA-SSR) showed a statistically significant correlation with the gefitinib response and was appeared to be a useful predictive marker of the development of clinical outcome containing skin rashes with gefitinib treatment. The other polymorphisms of EGFR were also associated with increased EGFR promoter activity. EGFR gene mutations and polymorphisms were also associated with EGFR kinase inhibitors response and toxicity.展开更多
47 senile non-parvicellular lung cancer patients at stage Ⅲ or Ⅳ were randomly divided into a treatment group (26 cases) treated by radiotherapy plus traditional Chinese medicine (TCM) and a control group (21 cases)...47 senile non-parvicellular lung cancer patients at stage Ⅲ or Ⅳ were randomly divided into a treatment group (26 cases) treated by radiotherapy plus traditional Chinese medicine (TCM) and a control group (21 cases) treated only by radiotherapy for observation of the therapeutic effects.The patients in the treatment group orally took Chinese medicine during and after the radiotherapy.There was no obvious difference in short-term therapeutic effects between the two groups,but the long-term curative effects in the treatment group was obviously superior to that in the control group (P<0.05 or P<0.01).Conclusion:radiotherapy plus TCM can prolong the survival period for senile non-parvicellular lung cancer patients.展开更多
Objective: To analyze the clinical course and treatment result of lung metastases from breast cancer Method: 122 cases with lung metastases from breast cancer were treated with chemotherapy or chemotherapy plus end...Objective: To analyze the clinical course and treatment result of lung metastases from breast cancer Method: 122 cases with lung metastases from breast cancer were treated with chemotherapy or chemotherapy plus endocrine therapy, response was assessed according to WHO criteria and survival rate estimated using the life Table Results: The median time from initial treatment of primary tumor to lung metastases was 22 months Sites of common consecutive metastases were lung, liver and bone The overall response rate was 48% with a CR rate of 15% Compared to non DDP encompassing regimen, the CR rate was higher in DDP based chemotherapy (7% versus 21%, P <0 05) with a longer median survival time (MST) The PR rate was higher in regimens containing anthracycline (48%) than in those without anthracycline (20%, P <0 01) The response rate was similar between chemotherapy and chemotherapy plus endocrine therapy ( P >0 05) No difference in MST was observed between patients receiving anthracycline and non anthracycline encompassing regimens The 1 , 3 , 5 , and 10 year survival rate was 77%, 22%, 11%, and 10%, respectively Conclusion: Size of primary tumor, the length of disease free interval, the number of lung metastases may provide additional information for predicting patients survival after treatment of lung metastases Combination chemotherapy, especially DDP based chemotherapy may prolong survival time of patients with lung metastases from breast cancer展开更多
背景与目的肺癌是全球最常见的恶性肿瘤之一,目前肺癌筛查和治疗策略不断完善,但其5年生存率仍然很低,严重危害人类的健康。因此探索新的生物标志物,提供个体化治疗并改善患者预后至关重要。铜死亡是一种新发现的细胞死亡类型,是由于细...背景与目的肺癌是全球最常见的恶性肿瘤之一,目前肺癌筛查和治疗策略不断完善,但其5年生存率仍然很低,严重危害人类的健康。因此探索新的生物标志物,提供个体化治疗并改善患者预后至关重要。铜死亡是一种新发现的细胞死亡类型,是由于细胞内过量铜离子积累,最终导致细胞死亡,已有研究提示其与肺腺癌(lung adenocarcinoma,LUAD)的发生发展密切相关。本研究基于肿瘤基因组图谱(The Cancer Genome Atlas,TCGA)数据库,探究铜死亡相关基因(cuproptosis related gene,CRGs)与LUAD预后之间的关联,建立预后风险模型并分析CRGs与LUAD免疫细胞浸润之间的相互作用,为肺腺癌患者的治疗及预后提供参考。方法从TCGA数据库中下载LUAD组织和癌旁或正常肺组织的RNA-seq数据,从基因型-组织表达资料库(Genotype-tissue Expression,GTEx)下载正常肺组织的RNA-seq数据,并从基因表达综合数据库(Gene Expression Omnibus,GEO)下载462例肺腺癌数据作为验证,采用单因素Cox和Lasso-Cox回归分析构建评估预后的风险评分模型,用受试者工作特征(receiver operating characteristic,ROC)曲线及校准曲线评价模型的预测能力。并进一步对高、低风险组进行免疫相关和药物敏感性分析。结果共得到1656个CRGs,其中有1356个存在差异表达的CRGs,基于单因素Cox和Lasso-Cox回归分析筛选出13个CRGs构建预后风险模型,ROC曲线1、3、5年的曲线下面积(area under the curve,AUC)分别为0.749、0.740、0.689。进一步研究高、低风险组之间免疫相关功能和免疫检查点差异分析。高风险组对萨沃替尼、帕博西尼、阿糖胞苷等药物敏感性更高,更容易从免疫治疗中获益。结论基于13个CRGs构建的风险模型具有较好的预后价值,可以辅助LUAD患者进行个体化治疗,为LUAD的治疗及预后研究提供了重要理论依据。展开更多
文摘The phamacogenetics is being used to predict whether the selected chemotherapy will be really effective and tolerable to the patient. Irinotecan,oxidized by CYP3A4 to produce inactive compounds,is used for treatment of various cancers including advanced non small cell lung cancer (NSCLC) patients. CYP3A4*16B polymorphism was associated with decreased metabolism of irrinotecan. Irinotecan is also metabolized by carboxylesterase to its principal active metabolite,SN-38,which is subsequently glucuronidated by UGT1As to form the inactive compound SN-38G. UGT1A1*28 and UGT1A1*6 polymorphisms were useful for predicting severe toxicity with NSCLC patients treated with irinotecan-based chemotherapy. Platinum-based compounds (cisplatin,carboplatin) are being used in combination with new cytotoxic drugs such as gemcitabine,paclitaxel,docetaxel,or vinorelbine in the treatment of advanced NSCLC. Cisplatin activity is mediated through the formation of cisplatin-DNA adducts. Gene polymorphisms of DNA repair factors are therefore obvious candidates for determinants of repair capacity and chemotherapy efficacy. ERCC1,XRCC1 and XRCC3 gene polymorphisms were a useful marker for predicting better survival in advanced NSCLC patients treated with platinum-based chemotherapy. XPA and XPD polymorphisms significantly increased response to platinum-based chemotherapy. These DNA repair gene polymorphisms were useful as a predictor of clinical outcome to the platinum-based chemotherapy. EGFR kinase inhibitors induce dramatic clinical responses in NSCLC patients with advanced disease. EGFR gene polymorphism in intron 1 contains a polymorphic single sequence dinucleotide repeat (CA-SSR) showed a statistically significant correlation with the gefitinib response and was appeared to be a useful predictive marker of the development of clinical outcome containing skin rashes with gefitinib treatment. The other polymorphisms of EGFR were also associated with increased EGFR promoter activity. EGFR gene mutations and polymorphisms were also associated with EGFR kinase inhibitors response and toxicity.
文摘47 senile non-parvicellular lung cancer patients at stage Ⅲ or Ⅳ were randomly divided into a treatment group (26 cases) treated by radiotherapy plus traditional Chinese medicine (TCM) and a control group (21 cases) treated only by radiotherapy for observation of the therapeutic effects.The patients in the treatment group orally took Chinese medicine during and after the radiotherapy.There was no obvious difference in short-term therapeutic effects between the two groups,but the long-term curative effects in the treatment group was obviously superior to that in the control group (P<0.05 or P<0.01).Conclusion:radiotherapy plus TCM can prolong the survival period for senile non-parvicellular lung cancer patients.
文摘Objective: To analyze the clinical course and treatment result of lung metastases from breast cancer Method: 122 cases with lung metastases from breast cancer were treated with chemotherapy or chemotherapy plus endocrine therapy, response was assessed according to WHO criteria and survival rate estimated using the life Table Results: The median time from initial treatment of primary tumor to lung metastases was 22 months Sites of common consecutive metastases were lung, liver and bone The overall response rate was 48% with a CR rate of 15% Compared to non DDP encompassing regimen, the CR rate was higher in DDP based chemotherapy (7% versus 21%, P <0 05) with a longer median survival time (MST) The PR rate was higher in regimens containing anthracycline (48%) than in those without anthracycline (20%, P <0 01) The response rate was similar between chemotherapy and chemotherapy plus endocrine therapy ( P >0 05) No difference in MST was observed between patients receiving anthracycline and non anthracycline encompassing regimens The 1 , 3 , 5 , and 10 year survival rate was 77%, 22%, 11%, and 10%, respectively Conclusion: Size of primary tumor, the length of disease free interval, the number of lung metastases may provide additional information for predicting patients survival after treatment of lung metastases Combination chemotherapy, especially DDP based chemotherapy may prolong survival time of patients with lung metastases from breast cancer
文摘背景与目的肺癌是全球最常见的恶性肿瘤之一,目前肺癌筛查和治疗策略不断完善,但其5年生存率仍然很低,严重危害人类的健康。因此探索新的生物标志物,提供个体化治疗并改善患者预后至关重要。铜死亡是一种新发现的细胞死亡类型,是由于细胞内过量铜离子积累,最终导致细胞死亡,已有研究提示其与肺腺癌(lung adenocarcinoma,LUAD)的发生发展密切相关。本研究基于肿瘤基因组图谱(The Cancer Genome Atlas,TCGA)数据库,探究铜死亡相关基因(cuproptosis related gene,CRGs)与LUAD预后之间的关联,建立预后风险模型并分析CRGs与LUAD免疫细胞浸润之间的相互作用,为肺腺癌患者的治疗及预后提供参考。方法从TCGA数据库中下载LUAD组织和癌旁或正常肺组织的RNA-seq数据,从基因型-组织表达资料库(Genotype-tissue Expression,GTEx)下载正常肺组织的RNA-seq数据,并从基因表达综合数据库(Gene Expression Omnibus,GEO)下载462例肺腺癌数据作为验证,采用单因素Cox和Lasso-Cox回归分析构建评估预后的风险评分模型,用受试者工作特征(receiver operating characteristic,ROC)曲线及校准曲线评价模型的预测能力。并进一步对高、低风险组进行免疫相关和药物敏感性分析。结果共得到1656个CRGs,其中有1356个存在差异表达的CRGs,基于单因素Cox和Lasso-Cox回归分析筛选出13个CRGs构建预后风险模型,ROC曲线1、3、5年的曲线下面积(area under the curve,AUC)分别为0.749、0.740、0.689。进一步研究高、低风险组之间免疫相关功能和免疫检查点差异分析。高风险组对萨沃替尼、帕博西尼、阿糖胞苷等药物敏感性更高,更容易从免疫治疗中获益。结论基于13个CRGs构建的风险模型具有较好的预后价值,可以辅助LUAD患者进行个体化治疗,为LUAD的治疗及预后研究提供了重要理论依据。
